Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Aug;112(4):1043–1048. doi: 10.1111/j.1476-5381.1994.tb13188.x

Novel histamine H3 receptor antagonists: affinities in an H3 receptor binding assay and potencies in two functional H3 receptor models.

E Schlicker 1, M Kathmann 1, S Reidemeister 1, H Stark 1, W Schunack 1
PMCID: PMC1910257  PMID: 7952862

Abstract

1. We determined the affinities of ten novel H3 receptor antagonists in an H3 receptor binding assay and their potencies in two functional H3 receptor models. The novel compounds differ from histamine in that the aminoethyl side chain is replaced by a propyl or butyl chain linked to a polar group (amide, thioamide, ester, guanidine, guanidine ester or urea) which, in turn, is connected to a hexocyclic ring or to an alicyclic ring-containing alkyl residue [corrected]. 2. The specific binding of [3H]-N alpha-methylhistamine to rat brain cortex membranes was monophasically displaced by each of the ten compounds at pKi values ranging from 7.56 to 8.68. 3. Inhibition by histamine of the electrically evoked tritium overflow from mouse brain cortex slices preincubated with [3H]-noradrenaline was antagonized by the ten compounds and the concentration-response curve was shifted to the right with apparent pA2 values ranging from 7.07 to 9.20. 4. The electrically induced contraction in guinea-pig ileum strips (which was abolished by atropine) was inhibited by the H3 receptor agonists R-(-)-alpha-methylhistamine (pEC50 7.76), N alpha-methylhistamine (7.90) and imetit (8.18). The concentration-response curve of R-(-)-alpha-methylhistamine was shifted to the right by thioperamide (apparent pA2 8.79) and by the ten novel compounds (range of pA2 values 6.64-8.81). 5. The affinities and potencies were compared by linear regression analysis. This analysis was extended to thioperamide, the standard H3 receptor antagonist, which is also capable of differentiating between H3A and H3B sites.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1043

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arrang J. M., Garbarg M., Lancelot J. C., Lecomte J. M., Pollard H., Robba M., Schunack W., Schwartz J. C. Highly potent and selective ligands for histamine H3-receptors. Nature. 1987 May 14;327(6118):117–123. doi: 10.1038/327117a0. [DOI] [PubMed] [Google Scholar]
  2. Arrang J. M., Garbarg M., Schwartz J. C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983 Apr 28;302(5911):832–837. doi: 10.1038/302832a0. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. De Lean A., Hancock A. A., Lefkowitz R. J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol. 1982 Jan;21(1):5–16. [PubMed] [Google Scholar]
  5. Garbarg M., Arrang J. M., Rouleau A., Ligneau X., Tuong M. D., Schwartz J. C., Ganellin C. R. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J Pharmacol Exp Ther. 1992 Oct;263(1):304–310. [PubMed] [Google Scholar]
  6. Hoyer D., Middlemiss D. N. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci. 1989 Apr;10(4):130–132. doi: 10.1016/0165-6147(89)90159-4. [DOI] [PubMed] [Google Scholar]
  7. Kathmann M., Schlicker E., Detzner M., Timmerman H. Nordimaprit, homodimaprit, clobenpropit and imetit: affinities for H3 binding sites and potencies in a functional H3 receptor model. Naunyn Schmiedebergs Arch Pharmacol. 1993 Nov;348(5):498–503. doi: 10.1007/BF00173209. [DOI] [PubMed] [Google Scholar]
  8. Leurs R., Timmerman H. The histamine H3-receptor: a target for developing new drugs. Prog Drug Res. 1992;39:127–165. doi: 10.1007/978-3-0348-7144-0_4. [DOI] [PubMed] [Google Scholar]
  9. McPherson G. A., Molenaar P., Raper C., Malta E. Analysis of dose-response curves and calculation of agonist dissociation constants using a weighted nonlinear curve fitting program. J Pharmacol Methods. 1983 Dec;10(4):231–241. doi: 10.1016/0160-5402(83)90017-7. [DOI] [PubMed] [Google Scholar]
  10. Schlicker E., Behling A., Lümmen G., Göthert M. Histamine H3A receptor-mediated inhibition of noradrenaline release in the mouse brain cortex. Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):489–493. doi: 10.1007/BF00176630. [DOI] [PubMed] [Google Scholar]
  11. Trendelenburg A. U., Limberger N., Starke K. Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit. Naunyn Schmiedebergs Arch Pharmacol. 1993 Jul;348(1):35–45. doi: 10.1007/BF00168534. [DOI] [PubMed] [Google Scholar]
  12. Vollinga R. C., Zuiderveld O. P., Scheerens H., Bast A., Timmerman H. A simple and rapid in vitro test system for the screening of histamine H3 ligands. Methods Find Exp Clin Pharmacol. 1992 Dec;14(10):747–751. [PubMed] [Google Scholar]
  13. West R. E., Jr, Zweig A., Shih N. Y., Siegel M. I., Egan R. W., Clark M. A. Identification of two H3-histamine receptor subtypes. Mol Pharmacol. 1990 Nov;38(5):610–613. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES